nAMD: Switching Therapies - what you need to know
Program Goal
Currently Available Anti-VEGF Therapies Used to Treat nAMD
12-Month Outcomes of Ranibizumab vs Aflibercept: Similar Rates of VA Improvement
Factors That Determine The Reason to Switch Therapies
EMR Study: Real World Ranibizumab Data Vs Benchmark Standards of Care
Real-World Visual Outcomes at Centers Across UK Differ From Randomized Trials
Is It Beneficial for a Patient to Switch?
Results May Vary After Switching Therapies
Two Main Reasons for Switching Therapies
Visual Function of Patient is Most Important
Can Anatomical Endpoints Guide Decisions to Switch Therapies?
Benefit of Switching: Theory
Switching From Ranibizumab to Aflibercept: Real-Life Data
Switching From Ranibizumab to Aflibercept: Real-Life Data (cont)
Significance of Switching: Study Results
The Mechanisms of Tachyphylaxis
Meta-Analysis of Studies of Patients With Treatment Resistant nAMD: Methods
Meta-Analysis Indicates High Number of Injections May Cause Resistance
Concepts of Tachyphylaxis: More Data is Needed
Concepts of Tachyphylaxis: Change in Underlying Disease
Factors That Involve Decisions to Switch Therapies
CATT Study: Results Show Discontinuous Therapy Inferior to Continuous Therapy
Real-Life Data Studies May Differ From Clinical Trial Data
Response to Anti-VEGF Therapy in nAMD
Is a Loading Phase Needed After Switching?
Patient Case Scenario
Switching Study: Ranibizumab to Aflibercept to Ranibizumab
Concluding Remarks
Abbreviations
Abbreviations (cont)